Yuhan000100.KS

About Yuhan

Yuhan Corporation is one of Korea's oldest pharmaceutical companies, founded in 1926 by entrepreneur Yoo Il-han, who bequeathed his ownership to a charitable foundation, an arrangement that still distinguishes the company's governance. Its business spans prescription drugs, over-the-counter staples, and active pharmaceutical ingredients, complemented by a long-standing consumer-hygiene joint venture with Kimberly-Clark. In new-drug development, Yuhan discovered the lung-cancer therapy lazertinib, licensed to Johnson & Johnson's Janssen unit, from which it earns milestone payments and royalties. Revenue mixes domestic drug sales, consumer products, ingredient exports, and licensing income.

Governance is the signature structural feature: with foundation ownership in place of a controlling family, Yuhan is frequently cited as an outlier in Korean corporate governance, and professional managers rotate through the top job. For growth, investors focus on the royalty stream from partnered oncology assets, which introduces lumpiness tied to a multinational partner's commercial execution in Western markets, a dependence on decisions made outside Seoul. The base business is defensive and domestic, subject to Korean drug-pricing rules. A record of steady dividends supports its standing among governance-screened portfolios.

Yuhan was founded in 1926 by Yoo Il-han, a Korean-American businessman who returned from the United States to sell medicines under the willow-tree trademark, building a company famous for staples like the Antiphlamine liniment introduced in the 1930s. Yoo pioneered practices then radical in Korea, including professional management, employee stock ownership, and transparent taxation, and on his death in 1971 left his fortune to the public-interest foundation that remains a core shareholder. The company formed its consumer-products joint venture with Kimberly-Clark in 1970 and has been led ever since by salaried professional executives rather than a controlling family.

Yuhan's revenue rests on several legs. It markets its own prescription and over-the-counter medicines domestically and distributes in-licensed drugs from multinationals, leveraging one of Korea's strongest hospital and pharmacy sales networks. A chemicals arm exports active ingredients to global drugmakers, and the Kimberly-Clark joint venture contributes steady equity income from diapers and tissue products. The newest leg is out-licensing: Yuhan scouts compounds from Korean biotechs, develops them toward proof of concept, and licenses them to global partners, as with its lung-cancer therapy, earning milestones and royalties. This open-innovation relay model differentiates it from more vertically integrated rivals.

Company profile by LineVest editorial. Journalism, not investment advice. Commission a full DART-based report on Yuhan →